University of St Andrews spin-out Pneumagen has reported positive findings from three in-vitro studies of Neumifil and other multivalent carbohydrate binding modules (mCBMs) to prevent infection by coronaviruses, including SARS-CoV-2.
The drug candidates are based on the company’s GlycoTarge platform, which can be used to create glycan targeted mCBMs from bacterial glycosidases.
These mCBMs could help prevent and also treat respiratory tract infections (RTIs) via attachment to epithelial cell surface glycan receptors in the respiratory tract, said Pneumagen.
Neumifil is the company’s lead candidate already being developed as a universal therapy for respiratory tract infections (RTIs), including influenza virus (IFV) and respiratory